about
fosfestrolprednisolonedienogestliarozoletriptorelingoserelinaminoglutethimidemethylprednisolone hemisuccinatemedroxyprogesterone acetatetestolactonetoremifenemegestroltamoxifenEstramustineTibolonemitotaneflutamideanastrozoleOctreotidemethyltestosteronedexamethasoneprednisonechlorotrianisenefadrozoleFulvestrantHexestrolmedrogestonemegestrol acetatenafoxidineleuprolide
P2868
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial CancerTestosterone Plus Finasteride Treatment After Spinal Cord InjuryAdjuvant Endocrine Therapy in Early Stage Breast Cancer: Adherence and Clinical OutcomeStudy of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer PatientsStudy of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or HypogonadismThe Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric ApproachThe Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer
P4844
Q1003185-BC5F6859-D3CB-4040-931D-440B3AEBD6ECQ11426176-6D2B0969-C07B-4349-ACE1-10C20C9F0C03Q139160-90DF743A-F00D-4A51-8212-224CC4083281Q15633974-34FC46CA-BA2B-412B-8D28-BE1131C200B1Q1992452-BB5F8918-A64A-4C31-BF77-04C095CF2353Q1992653-A8A17CF9-8D29-46C5-9DEC-303E39BC1526Q241150-681F59B3-BB7D-492D-AC39-4118232A0047Q27262132-64E5DC7C-3C2B-4721-A1A4-70FC2915F914Q2823834-15FD92BC-7BC8-4754-B82E-8582EBCDF4F3Q3985253-6584C0F7-09C5-4585-819E-39018167D3DFQ3993743-47E86701-564B-4E30-A3D6-AE111D1A257FQ410513-6DCE07DF-D8E7-4945-986B-9C4E63715F03Q412178-B81D9357-5D6F-4A1D-AD2F-14DCCB8C5026Q412939-ED93E563-D5FD-4F85-952F-679378673560Q413805-AC4E3E13-F647-43AA-A714-C9A9829B69C5Q417465-7649F8DD-1929-4C9F-ABC9-8901CBE85E0BQ418669-5A4C2879-EFEF-4DD5-8B6A-3BCD22538015Q419143-BD93D99F-7B77-4D89-860C-E87F49864BA8Q419935-620DEB95-A2E2-4606-AF36-8EEA27B3719CQ421768-72E66B3D-0E40-431D-84EB-17822B5C79E3Q422252-C5A4D4E8-C9F3-47EC-B279-97FCB263B4D0Q424972-4ADD0F87-47B7-4F17-BA96-DBE574698DC0Q5103213-13454BD3-D79B-42EE-8D68-9828A50A26DEQ5429279-EF160B0B-CD1A-416E-8E69-709ED1D9FF8AQ5508491-ED8C6F15-AF0B-4D62-8BF0-A7753B79E558Q5896882-125F21A0-FBAB-4BC6-A80A-A5B1EAD927A2Q6807285-336270B5-EDC9-4473-B86B-073A09E71E08Q6808975-31C9B0F0-308D-4F3A-8F44-A44731FE8C4EQ6958201-7FCFDA9D-3178-4ECC-B9B4-8E493BE49328Q907160-DC493E14-333C-47D7-9925-DA2077BFB621
P2868
Q61902537-564D8D8B-A582-4E33-B3CB-D0B49BDEF925Q63571433-2C272272-0F41-4FE2-84B4-EA614EF74986Q63595821-934962FD-B8E0-4737-9539-D8C4196B3562Q63831972-E5C2ABDD-91EF-49D6-B254-55B0C658D871Q64184233-1B0B9496-3579-432C-9D84-003D16072E43Q64221788-D3389521-9FF2-4E84-AAC0-50691B4D30E6Q65359674-D608FE32-8951-471F-AFF7-598E13A10B5EQ65377442-66D224E1-682E-4C01-A113-1D09F46ADD89
P4844
description
Antineoplastic agents that are ...... lus, by surgery or pharmacolog
@en
name
hormonal antineoplastic agents
@en
hormonelt antineoplastisk middel
@nn
type
label
hormonal antineoplastic agents
@en
hormonelt antineoplastisk middel
@nn
altLabel
Antineoplastic Agents, Hormonal
@en
Antineoplastic Drugs, Hormonal
@en
Antineoplastic Hormonal Agents
@en
Antineoplastic Hormonal Drugs
@en
Antineoplastics, Hormonal
@en
Hormonal Agents, Antineoplastic
@en
Hormonal Antineoplastic Drugs
@en
Hormonal Antineoplastics
@en
antineoplastisk middel, hormonelt
@nn
antineoplastiske middel, hormonelle
@nn
prefLabel
hormonal antineoplastic agents
@en
hormonelt antineoplastisk middel
@nn
P486
P279
P486
P672
D27.505.954.248.169